SG11202111387YA - Oligonucleotide compositions and methods of use thereof - Google Patents
Oligonucleotide compositions and methods of use thereofInfo
- Publication number
- SG11202111387YA SG11202111387YA SG11202111387YA SG11202111387YA SG11202111387YA SG 11202111387Y A SG11202111387Y A SG 11202111387YA SG 11202111387Y A SG11202111387Y A SG 11202111387YA SG 11202111387Y A SG11202111387Y A SG 11202111387YA SG 11202111387Y A SG11202111387Y A SG 11202111387YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- oligonucleotide compositions
- oligonucleotide
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962838763P | 2019-04-25 | 2019-04-25 | |
PCT/US2020/029959 WO2020219983A2 (en) | 2019-04-25 | 2020-04-24 | Oligonucleotide compositions and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111387YA true SG11202111387YA (en) | 2021-11-29 |
Family
ID=72941792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111387YA SG11202111387YA (en) | 2019-04-25 | 2020-04-24 | Oligonucleotide compositions and methods of use thereof |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230145795A1 (en) |
EP (1) | EP3959318A4 (en) |
AU (1) | AU2020262485A1 (en) |
BR (1) | BR112021021214A2 (en) |
CA (1) | CA3137741A1 (en) |
MX (1) | MX2021012981A (en) |
SG (1) | SG11202111387YA (en) |
WO (1) | WO2020219983A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2872485B1 (en) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
KR102213609B1 (en) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | Chiral control |
MA43072A (en) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
WO2017160741A1 (en) | 2016-03-13 | 2017-09-21 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
JP7296882B2 (en) | 2016-11-23 | 2023-06-23 | ウェイブ ライフ サイエンシズ リミテッド | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
CN111050806A (en) | 2017-06-02 | 2020-04-21 | 波涛生命科学有限公司 | Oligonucleotide compositions and methods of use thereof |
WO2018223081A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
WO2018237194A1 (en) | 2017-06-21 | 2018-12-27 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
EP3664816A4 (en) | 2017-08-08 | 2021-05-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
CN111108096A (en) | 2017-09-18 | 2020-05-05 | 波涛生命科学有限公司 | Oligonucleotide preparation technology |
SG11202001783YA (en) | 2017-10-12 | 2020-03-30 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
US11332733B2 (en) | 2018-02-12 | 2022-05-17 | lonis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
WO2023075766A1 (en) * | 2021-10-27 | 2023-05-04 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
WO2023076352A2 (en) * | 2021-10-27 | 2023-05-04 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
WO2023183556A2 (en) * | 2022-03-24 | 2023-09-28 | Amcyte Pharma, Inc. | Treatment for retinal disorders |
WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
WO2024073705A1 (en) * | 2022-09-30 | 2024-04-04 | University Of Massachusetts | Ocular delivery of oligonucleotides |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10202599B2 (en) * | 2011-08-11 | 2019-02-12 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
AU2015207773B2 (en) * | 2014-01-16 | 2021-06-17 | Wave Life Sciences Ltd. | Chiral design |
AU2016222546B2 (en) * | 2015-02-26 | 2020-01-23 | Ionis Pharmaceuticals, Inc. | Allele specific modulators of P23H rhodopsin |
MA43072A (en) * | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
CR20180233A (en) * | 2015-10-09 | 2018-05-25 | Wave Life Sciences Ltd | OLIGONUCLEOTID COMPOSITIONS AND THEIR METHODS |
MA45270A (en) * | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
-
2020
- 2020-04-24 BR BR112021021214A patent/BR112021021214A2/en unknown
- 2020-04-24 EP EP20794544.5A patent/EP3959318A4/en active Pending
- 2020-04-24 MX MX2021012981A patent/MX2021012981A/en unknown
- 2020-04-24 CA CA3137741A patent/CA3137741A1/en active Pending
- 2020-04-24 WO PCT/US2020/029959 patent/WO2020219983A2/en unknown
- 2020-04-24 AU AU2020262485A patent/AU2020262485A1/en active Pending
- 2020-04-24 US US17/605,997 patent/US20230145795A1/en active Pending
- 2020-04-24 SG SG11202111387YA patent/SG11202111387YA/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021012981A (en) | 2022-01-18 |
CA3137741A1 (en) | 2020-10-29 |
AU2020262485A1 (en) | 2021-11-11 |
EP3959318A2 (en) | 2022-03-02 |
WO2020219983A2 (en) | 2020-10-29 |
EP3959318A4 (en) | 2023-10-25 |
WO2020219983A3 (en) | 2020-12-03 |
US20230145795A1 (en) | 2023-05-11 |
BR112021021214A2 (en) | 2022-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291933A (en) | Oligonucleotide compositions and methods of use thereof | |
SG11202111387YA (en) | Oligonucleotide compositions and methods of use thereof | |
IL277889A (en) | Oligonucleotide compositions and methods of use thereof | |
SG11202010131QA (en) | Oligonucleotide compositions and methods of use thereof | |
EP4037695A4 (en) | Oligonucleotide compositions and methods of use thereof | |
SG11202111386UA (en) | Oligonucleotide compositions and methods of use thereof | |
EP3965780A4 (en) | Oligonucleotide compositions and methods of use thereof | |
EP3630199A4 (en) | Oligonucleotide compositions and methods of use thereof | |
EP3630788A4 (en) | Oligonucleotide compositions and methods of use thereof | |
EP3630789A4 (en) | Oligonucleotide compositions and methods of use thereof | |
IL284882A (en) | Oligonucleotide compositions and methods thereof | |
GB2582482B (en) | CASZ compositions and methods of use | |
SG11202105626TA (en) | Oligonucleotide compositions and methods thereof | |
EP4114939A4 (en) | Oligonucleotide compositions and methods thereof | |
GB2582100B (en) | CAS12C Compositions and methods of use | |
ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
IL276135A (en) | Compositions and methods of use | |
ZA201906169B (en) | Synthekine compositions and methods of use | |
IL288259A (en) | Modified gapmer oligonucleotides and methods of use | |
GB202105087D0 (en) | Microbial compositions and methods of use | |
EP4081231A4 (en) | Compositions comprising microbes and methods of use and making thereof | |
IL285247A (en) | Enhanced nitrate compositions and methods of use | |
SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
IL282533A (en) | Oligosaccharide compositions and methods of use thereof | |
ZA201908276B (en) | Charge-tagged nucleotides and methods of use thereof |